Clinical Trials
12 trialsNCT05456191 2026-05-27
ASC4START
Novartis
Phase 3 Active not recruiting
NCT04562389 2026-04-09
SENTRY
Karyopharm Therapeutics Inc
Phase 3 Active not recruiting
NCT04279847 2026-04-01
LIMBER
Incyte Corporation
Phase 1 Active not recruiting
NCT04509700 2025-12-10
Rollover Study to Provide Continued Treatment for Participants With B-Cell Malignancies Previously Enrolled in Studies of Parsaclisib (INCB050465)
Incyte Corporation
Phase 2 Active not recruiting
NCT04576156 2025-12-04
A Study Comparing Imetelstat Versus Best Available Therapy for the Treatment of Intermediate-2 or High-risk Myelofibrosis (MF) Who Have Not Responded to Janus Kinase (JAK)-Inhibitor Treatment
Geron Corporation
Phase 3 Active not recruiting
NCT04285086 2025-08-13
SURPASS ET
PharmaEssentia
Phase 3 Active not recruiting
NCT05482971 2025-08-13
A Single-arm, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of P1101 in Adults With ET
PharmaEssentia
Phase 2 Active not recruiting
NCT04717414 2025-07-10
INDEPENDENCE
Celgene
Phase 3 Active not recruiting
NCT04603001 2025-06-27
Study of Oral LY3410738 in Patients With Advanced Hematologic Malignancies With IDH1 or IDH2 Mutations
Eli Lilly and Company
Phase 1 Active not recruiting
NCT01761968 2025-04-30
Long-term Study Evaluating the Effect of Givinostat in Patients With Chronic Myeloproliferative Neoplasms
Italfarmaco
Phase 2 Active not recruiting
NCT04041050 2025-02-14
A Study Evaluating Safety and Tolerability, and Pharmacokinetics of Navitoclax Monotherapy and in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasm
AbbVie
Phase 1 Active not recruiting
NCT03386513 2024-12-16
Study of IMGN632 in Patients With Untreated BPDCN and Relapsed/Refractory BPDCN
AbbVie
Phase 1/2 Active not recruiting